A Phase 2, Safety and Dose-Finding Study in Treatment-Naive, Pre-Pubertal, Growth Hormone-Deficient Children
- Registration Number
- NCT02092077
- Lead Sponsor
- Teva Pharmaceutical Industries, Ltd.
- Brief Summary
The purpose of this study is to support selection of an appropriate safe and efficacious dose for study in further development.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 65
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description TV-1106 0.554 mg TV-1106 - somatropin 0.033 mg/kg/day somatropin Dosages may be adjusted according to findings and as necessary TV-1106 0.924 mg/kg TV-1106 - TV-1106 1.20 mg/kg TV-1106 -
- Primary Outcome Measures
Name Time Method Height velocity (HV) Month 6
- Secondary Outcome Measures
Name Time Method Height velocity standard deviation score (HV-SDS) Months 6 and 12 Height velocity (HV) Month 12 Number of participants with adverse events up to 24 months Height standard deviation score (H-SDS) Months 6 and 12
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
Trial Locations
- Locations (34)
Teva Investigational Site 68016
🇧🇾Minsk, Belarus
Teva Investigational Site 59060
🇧🇬Varna, Bulgaria
Teva Investigational Site 81022
🇬🇪Tbilisi, Georgia
Teva Investigational Site 81023
🇬🇪Tbilisi, Georgia
Teva Investigational Site 81025
🇬🇪Tbilisi, Georgia
Teva Investigational Site 63046
🇬🇷Athens, Greece
Teva Investigational Site 51159
🇭🇺Budapest, Hungary
Teva Investigational Site 51160
🇭🇺Budapest, Hungary
Teva Investigational Site 51181
🇭🇺Szombathely, Hungary
Teva Investigational Site 80052
🇮🇱Afula, Israel
Scroll for more (24 remaining)Teva Investigational Site 68016🇧🇾Minsk, Belarus